No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
LVTX241220P2500
- 0.00
- 0.000.00%
15min DelayClose Dec 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-125.23%PremiumDec 20, 2024Expiry Date1.39Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.48Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Leerink Partners Downgrades LAVA Therapeutics(LVTX.US) to Hold Rating, Announces Target Price $2
Hold Rating on LAVA Therapeutics Amid Uncertainty and Program Discontinuation
Express News | LAVA Therapeutics NV : Leerink Partners Cuts to Market Perform From Outperform
JMP Securities Downgrades LAVA Therapeutics to Market Perform, Maintains Price Target to $6
LAVA Therapeutics Analyst Ratings
JMP Securities Downgrades LAVA Therapeutics(LVTX.US) to Hold Rating